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Intro
Because of the controversy regarding the issue of pancreatitis with the use
lncretin hormones, such as gastric inhibitory peptide and glucagon-like
of exenatide, the manufacturer has recently made an addition to the packpeptide-1 (GLP-1 ), are produced in the intestines, and their combined ef- age insert pertaining to patient monitoring.6 The warning recognizes that
fects are known as the incretin effect. 1 Glucagon-like peptide 1 (GLP-1)
patients should be monitored for symptoms of pancreatitis when treatment
stimulates glucose-dependent insulin secretion, inhibits postprandial
is started on the medication or if the dose is increased. If symptoms are
glucagon secretion, and slows gastric emptying, thus reducing appetite.
consistent for diagnosis of pancreatitis, treatment should be discontinued
Endogenous GLP-1 is degraded rapidly by the enzyme dipeptidyl peptiimmediately and the patient should be appropriately managed. These
dase-4 (DPP-4), resulting in an extremely short half-life. Newer treatpatients are then ineligible for any future treatment with exenatide.
ments, such as exenatide, liraglutide and exenatide long-acting release
(LAR), have been developed as medications that exert GLP-1 activity
The FDA also has received 78 cases of altered renal function in patients
and yet resist DPP-4 inactivation. Exenatide was approved by the FDA
receiving exenatide treatment (62 acute, 16 renal insufficiency). 7
in 2005 as an adjunct therapy for type 2 diabetes mellitus (T2DM). It
Initial symptoms occurred three days to two years after initiation of
was the first incretin mimetic to demonstrate a decrease in hemoglobin
exenatide treatment in patients who were 23-83 years old. Fourteen of
A1C (HbA10) via glycemic control (average 1 percent reduction) and a
these patients had a past medical history of chronic kidney disease, a
significant decrease in body weight (1 .6 - 5.3 kg reduction). 2•3 Liraglutide contraindication for exenatide treatment, and 95 percent had at least
is the newest GLP-1 mimetic to be approved for T2DM, gaining approval one risk factor for altered kidney function, such as cardiac insufficiency,
in early 2010. 1 Unlike exenatide, which needs to be dosed twice daily,
hypertension, pancreatitis, rhabdomyolysis or urinary tract infection.
liraglutide is designed for once-daily dosing. A long-acting exenatide
Several patients were also at increased risk due to the use of antiretroviproduct, Bydureon® (exenatide LAR), is currently being developed
rals, antihypertensives, diuretics or NSAIDs. Four deaths were reported,
for once-weekly dosing. With the recent approval of liraglutide and the
and 91 percent of the treated patients required hospitalization. Symppossable approval of exenatide LAR, practitioners may find it valuable to toms improved in half of the patients after discontinuation of exenatide,
assess how each GLP-1 agent will fit into therapy for T2DM.
while 18 patients required dialysis and two required a renal transplant.
A precautionary statement has since been added to the labeling for
Exenatide
exenatide about treatment in patients with low creatinine clearance
The use of exenatide has widely been compared to the use of long-act(<50 mUmin). 5 Practitioners should continue to evaluate renal function
ing insulin for T2DM that is uncontrolled after initial therapies. Although
prior to exenatide treatment and throughout the progression of T2DM in
long-acting insulin may offer a greater decrease in HbA10 than exenatide, individual patients.
it causes weight gain, an unwanted effect in T2DM patients. 4 Over the
past five years, exenatide has established a role within T2DM therapy,
In late 2009, the FDA granted approval to use exenatide monotherapy
but long-term adverse events have also been noted with therapy.
in T2DM patients. The indication was granted after a study showed
improved glucose control and weight loss in a 24-week, randomized,
Like other new treatments for T2DM, the adverse drug reaction (ADR)
double-blind, placebo-controlled trial with 203 patients completing
profile of exenatide has been a cause for concern as long-term treatthe study. 8 Patients were randomized to 5 mcg twice-daily or 1omcg
ment data becomes available. The most common ADRs associated with twice-daily dosing, with the primary endpoint of decreased HbA10 and
exenatide treatment are nausea, vomiting, diarrhea and hypoglycemia. 5
secondary endpoints of fasting serum glucose, postprandial glucose and
However, most of these ADRs occur in combination therapy with other
weight. Results from the study showed a statistically significant decrease
T2DM medications and can be controlled through monitoring therapy. 5
in mean postprandial glucose (5 mcg-17.5mg/dl;10 mcg-18.7 mg/dl;
In addition to minor adverse reactions with exenatide, as of Jan. 1, 2010, placebo -5.2 mg/dl; p <0.001). Adverse events were similar between
the FDA has received 36 post-marketing reports of acute pancreatitis,
monotherapy and adjunct therapy, with nausea being the most common.
including six cases of hemorrhagic or necrotizing pancreatitis and two
The effectiveness of monotherapy compared to adjunct therapy has not
deaths. 2 However, it is important to note that 90 percent of these payet been studied.
tients had confounding factors for pancreatitis (obesity, hyperlipidemia,
hypertriglyceridemia, alcohol use).
Exenatide Long-acting Release (LAR)
Amylin Pharmaceuticals, Eli Lilly, and Alkermes have developed a
Thirty additional cases were subsequently reviewed by the FDA, none
long-acting exenatide product, Bydureon® (exenatide LAR), which is a
of which resulted in fatality. Initial symptoms began at an average of 34
once-weekly form of Byetta. Recently, the FDA denied approval due to
days after starting exenatide treatment, and abdominal pain was the most
clarifications needed on labeling, risk evaluation and mitigation strategy
common symptom, occurring in 23 of the 30 patients. Symptoms subsided (REMS), and the manufacturing process. At the time this article was writfor 22 of the 23 patients after exenatide was discontinued; however, reten, Bydureon was still not FDA-approved, but the following two studies
exposure caused a recurrence of symptoms in most patients.
demonstrate its potential in the treatment of T2DM.
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A30-week, randomized, non-inferiority, comparator-controlled, open-label
trial was performed comparing exenatide LAR 2 mg once-weekly to 1Omcg
exenatide twice-daily to assess safety, efficacy, tolerability and non-inferiority of the long-acting product. This product was considered to be non-inferior tt HbA10 change was <0.4 percent at week 30. A total of 295 weightstable patients with T2DM were included in this study. Subjects were either
naive to anti-diabetic treatment or were receiving one or more anti-diabetic
agents, including metformin, sulfonylureas, thiazolidinediones or a combination, for at least two months prior to the trial. Patients were randomized
into two groups, both receiving 5 mcg exenatide twice daily for three days,
then either 2 mg exenatide LAR for 30 weeks or 5 mcg exenatide twice
daily for 28 days followed by 1Omcg exenatide for the remainder of the 30week study. Results showed that, by week 10, the once-weekly group had
a signtticant decrease in HbA10, 1.9, compared to the twice-daily group, 1.5
(p=0.0023) despite patient background. The once-weekly group also had
77 percent of patients achieve HbA10 of '5.7 percent compared to 61 percent
in the twice-daily group (p=0.0039). The twice-daily group had 35 percent
of patients with a baseline HbA10 of ~9 percent achieve a final HbA1c of !.7
percent, while the once-weekly group had 65 percent of patients achieve
this level (p=0.02). Bodyweight decreased in both the exenatide and
exenatide LAR groups (-3.6 kg and-3.7 kg, respectively, p=0.89). Fasting
plasma glucose levels signtticantly decreased in the once-weekly group
versus the twice-daily group (-41.4 mg/dl and -25.2 mg/dl), respectively,
p<0.0001). In addition, the Diabetes Treatment Satisfaction Questionnaire
(DTSQ) showed a significant increase in satisfaction in the once-weekly
group. Adverse events for the once-weekly group were mild and included
nausea (26.4 percent) and injection site pruritus (17.6 percent) and were
significantly lower than the twice-daily group. No major hypoglycemic
events, occurrences of pancreatltis or significant abnormalities were found.
Overall, both exenatide and exenatide LAR decreased HbA10• Significant
reduction in HbA10 values due to continuous exposure to exenatide indicate
that glycemic control provided by the once-weekly formulation is not inferior
to the twice-daily formulation. 12
A52-week, randomized, multi-center, open-labeled trial was performed to
evaluate the effects of exenatide twice daily and exenatide once weekly on
treatment satisfaction and quality of life. Patient-reported outcome instruments included DTSQ and the Impact of Weight on Quality Of Ltte (IWOOLLite), which were given at baseline and weeks 30 and 52. Atotal of 295
patients were included - 148 in the 2 mg exenatide once-weekly and 147 in
the 1Omcg twice-daily during weeks 1-30, then 2 mg weekly for weeks 30-52.
Results of the DTSQ scores showed that at week 52, treatment satisfaction
improved in the once-weekly group. However, the IWQOL-Lite showed a
signtticant increase in satisfaction in both groups (P<0.001), but there was no
difference between them. After the twice-daily group switched to once-weekly
exenatide, improvement was seen for treatment satisfaction, convenience,
flexibility and continuance. In this group, the IWQOL-Llte also showed
significant improvement in physical function and public distress. Overall, the
weekly group had improved satisfaction with treatment convenience, flexibility
and public distress. All comparisons were shown to be statistically significant
with p<0.05. In addition, there was no difference in adverse events between
the groups. Overall, the once-weekly form had improvement in satisfaction,
convenience and flexibility. This could be a result of ease of use, less frequent
administration, and greater improvement in glucose control with perceived
hyperglycemia. The willingness to continue treatment could possibly improve
adherence and, thus, the outcome and control of T2DM. 13
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Liraglutide
Recently approved by the FDA, liraglutide is authorized for use in T2DM
as monotherapy or in combination with other anti-diabetic medications,
such as metformin, thiazolidinediones or sulfonylureas. 1 The approval was
delayed due to possible risk of medullary thyroid cancer, though malignant
tumors were only evident in animal trials. Novo Nordisk, the manufacturer
of liraglutide, funded the Liraglutide Effect and Action in Diabetes (LEAD
1-6) studies to establish the safety and efficacy of liraglutide. LEAD trials
1, 2, 4 and 5 primarily focused on combination therapy with liraglutide and
one or more oral antidiabetic medication, whereas LEAD-3 focused on
monotherapy, and LEAD-6 compared liraglutide with exenatide.
The LEAD-3 trial is a double-blinded, randomized trial performed to evaluate and compare the efficacy of liraglutide 1.2 mg and 1.8 mg once daily
with oral glimepiride 8 mg once daily as monotherapy for T2DM. 9 A total
of 746 participants with early T2DM were enrolled for the 52-week trial.
Participants were 18-80 years old, had an HbA10 between 7-11 percent,
had a BMI of !.40 kg/m 2, and had not used insulin or corticosteroids in the
previous three months. Participants were placed into one of three treatment groups: 1.2 mg liraglutide (n=251 ), 1.8 mg liraglutide (n=247), or 8
mg glimepiride (n=248). At the completion of the trial, HbA10 was reduced
more significantly in both liraglutide therapies than glimepiride (Table
1). Greater decreases in HbA10 were seen in patients previously treated
with lifestyle modifications only as compared to those patients who had
received oral anti-diabetic medications preceding the trial. Significantly
more patients achieved the American Diabetes Association HbA10 target of
less than 7 percent in the liraglutide therapies as compared to glimepiride
(table 1). No major hypoglycemia occurred, though minor hypoglycemia
occurred in all three groups. Nausea was more prevalent in liraglutide
groups but decreased after four weeks. The LEAD-3 trial was extended
another 52 weeks with 440 patients entering the extra year of treatment. 10
After the extension period was completed, mean reductions in HbA10 and
those reaching the target goal were significantly greater with liraglutide
1.2 mg and 1.8 mg than glimepiride (table 1). Treatment with liraglutide is
shown to be effective and safe as monotherapy and produces significant
greater reductions in HbA10 and FPG as compared with glimepiride.
The LEAD-6 trial is a 26-week randomized trial that compares the safety
and efficacy of liraglutide with exenatide in T2DM patients not adequately
controlled on metformin alone (n=127), a sulfonylurea alone (n=45), or
metformin plus a sulfonylurea (n=292}. 11 The464 participants were 18-80
years old, HbA10 between 7-11 percent, had a BMI of ~45 kg/m 2, and had
no previous insulin or exenatide. The patients continued on their treatment
and were randomly chosen to receive either 1.8 mg liraglutide once daily
(n=233) or 10 mcg exenatide twice daily (n=231). After 26 weeks, more
patients reached target HbA10 levels of <7 percent and had significantly
improved glycemic control with liraglutide than exenatide (table 1). Both
liraglutide and exenatide groups had similar weight reductions (table 1).
The incidence of nausea was initially similar in both groups but was less
persistent in the liraglutide group (p<0.0001). Treatment satisfaction was
measured using the Diabetes Treatment Satisfaction Questionnaire. Overall, treatment satisfaction was significantly better with liraglutide (n=161)
than with exenatide (n=143) (p=0.0004).
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Table 1. Efficacy of liraglutide (LIRA} as monotherapy in the treatment of T2DM. Results from two LEAD trials. LEAD-3 compared
LIRA against glimepiride (GLIM} for efficacy as monotherapy. LEAD-6 compared the efficacy of LIRA to exenatide (EXEN}. 9• 1°· 11
Study

LEAD-3
(Mono)
LEAD-3
(Mono
extension)
LEAD-6
(Vs. EXEN)

Therapy

LIRA 1.2mg
LIRA 1.8mg
GLIM 8mg
URA l.2mg
LIRA 1.8mg
GLIM 8mg
LIRA l.8mg
EXEN lOmcg

No.of
pts
251
247
248
149
154
137
233
231

Mean HbAlc (%)

Mean FPG (mg/dL)

Baseline

Change

Baseline

Change

8.3
8.3
8.4
8.1
8.1
8.0
8.2
8.1

-0.84
-1.14
-0.51
-1.1
-1.4
-0.6
-1.12
-0.79

167.4
171
171

-15.1
-26.8
-5.2
-23.4
-27
-5.4
-29
-10.8

-- *
--176.4
171

PtsatADA
target HbAlc
(%)
43
51
28
53
58
37
54
43

Body Wt (kg)
Baseline

cnange

92.5
92.8
93.4

-1.85
-2.26

93.1
93

+1.22
-2.1
-2.7
+1.1
-3.24
-2.87

*Baseline data not provided

Conclusion
New incretin based therapies have the possibility to influence the treatment of T2DM. Exenatide, liraglutide and exenatide LAR appear to be
relevant to the treatment of T2DM in their ability to decrease HbA,c while
reducing weight and may be appropriate as monotherapy agents for
some patients. Studies show that each agent exhibits a mild safety profile with modest differences in therapeutic outcomes. Currently, patient
preference and dosing schedule should be considered by the practitioner when determining the preferred agent for the patient. Additional
head-to-head trials may be beneficial to adequately compare exenatide,
liraglutide, or exenatide LAR to further determine the specific role in
therapy for each agent.
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